# Dana-Farber Cancer Institute: Early phase 1 study closed enrollment, 5 enrolled (Renal Carcinoma, Renal Cell Carcinoma)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Dana-Farber Cancer Institute |
| Sponsor type | Academic and hospital |
| Study | Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma |
| NCT ID | NCT06318871 |
| Phase | Early phase 1 |
| Status | active not recruiting |
| Conditions | Renal Carcinoma; Renal Cell Carcinoma; Urothelial Carcinoma; Chromophobe Renal Cell Carcinoma; Translocation Renal Cell Carcinoma |
| Intervention types | biological, drug |
| Target enrollment | 5 |
| Site countries | United States |
| Posted | 2024-03-19 |
| Planned start | 2024-08-28 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-23 |
| Last update posted | 2026-10-23 |

## Why this score
- Posted in the last two weeks.
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06318871). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.